SCHEMBL2597074

SCHEMBL2597074

OC1OCc2ccccc2O1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 2/20 0.58
MAOA P21397 7/20 0.39
MAOB P27338 7/20 0.39
AOC2 O75106 5/20 0.36
DAO P14920 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B3 P37058 1/20 0.34
CA2 P00918 1/20 0.34
LMNA P02545 1/20 0.33
DYRK1A Q13627 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3080227 0.78 NISCH (0.56) NISCHMAOAMAOBAOC2DAO
SCHEMBL30298419 0.76 NISCH (0.50) NISCHMAOAMAOBAOC2DAO
SCHEMBL4954350 0.75 NISCH (0.53) NISCHMAOAMAOBAOC2DAO
SCHEMBL2502594 0.75 NISCH (0.53) NISCHMAOAMAOBAOC2DAO
SCHEMBL23183087 0.75 NISCH (0.53) NISCHMAOAMAOBAOC2DAO
SCHEMBL7616087 0.75 NISCH (0.53) NISCHMAOAMAOBAOC2DAO
SCHEMBL19121185 0.75 NISCH (0.49) NISCHMAOAMAOBTSHRNPC1
SCHEMBL7086543 0.75 NISCH (0.67) NISCHHPGDTSHRNPC1RAB9A
SCHEMBL3850027 0.73 NISCH (0.51) NISCHMAOAMAOBAOC2NPC1
SCHEMBL28787079 0.72 NISCH (0.54) NISCHMAOAMAOBTSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115850251-A 3,4-methylenedioxyacetophenone imidazole oxime ether derivative, preparation method and application thereof, and medicine for treating Alzheimer's disease 西北农林科技大学 2023-03-28 CN claimed
CN-115850251-A 3,4-methylenedioxyacetophenone imidazole oxime ether derivative, preparation method and application thereof, and medicine for treating Alzheimer's disease 西北农林科技大学 2023-03-28 CN disclosed
CN-115175905-A ZESTE enhancer homolog 2 inhibitors and uses thereof 四川海思科制药有限公司 2022-10-11 CN disclosed
US-9220787-B2 Vitamin E conjugates, and their uses as antioxidants and prodrug delivery vehicles BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2015-12-29 US disclosed
US-20130210702-A1 Vitamin E Conjugates, and Their Uses as Antioxidants and Prodrug Delivery Vehicles BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE 2013-08-15 US disclosed
WO-2011146589-A2 VITAMIN E CONJUGATES, AND THEIR USES AS ANTIOXIDANTS AND PRODRUG DELIVERY VEHICLES BOARD OF SUPERVISORS OF LOUSIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210702-A1 Vitamin E Conjugates, and Their Uses as Antioxidants and Prodrug Delivery Vehicles TTPA, VSIR, FOLR1 NISCH 477/4885MAOA 1172/4885MAOB 1404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.